Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer

EGFR and HER-2 are important targets but none of the monoclonal antibodies or small molecule tyrosine kinase inhibitors specific for the HER members has been approved for the treatment of patients with ovarian cancers. In some studies, co-expression of other growth factor receptors has been associat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Puvanenthiran, Soozana, Essapen, Sharadah, Haagsma, Ben, Bagwan, Izhar, Green, Margaret, Khelwatty, Said Abdullah, Seddon, Alan, Modjtahedi, Helmout
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2018
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5929416/
https://ncbi.nlm.nih.gov/pubmed/29731973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24791
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak